|Articles|June 1, 2010

Health Economic Perspectives in Fibromyalgia: Focus on Pregabalin
Volume 16
Issue 5

eAppendix

Download PDF: eAppendix

Articles in this issue

over 15 years ago

Article

Impact of a Prior Authorization for Pregabalin on Health Plan Drug Expenditures

over 15 years ago

Article

Pregabalin: An Alpha2-delta (a2-d) Ligand for the Management of Fibromyalgia

over 15 years ago

Article

Financial and Clinical Characteristics of Fibromyalgia: A Case-Control Comparison

over 15 years ago

Article

Initial Use of Pregabalin, Patterns of Pain-Related Pharmacotherapy, and Healthcare Resource Use Among Older Patients With Fibromyalgia

over 15 years ago

Article

Introduction

over 15 years ago

Article

Participating Faculty

over 15 years ago

Article

Patterns of Healthcare Utilization and Cost in Patients With Newly Diagnosed Fibromyalgia

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Ambient AI Tool Adoption in US Hospitals and Associated Factors

ByFreddie Yang, MA,Ilana Graetz, PhD

January 27th 2026

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

ByTaylor I. Bucy, PhD,John P. McHugh, PhD,Dori A. Cross, PhD

January 26th 2026

Specialty and Operator Status Influence Electronic Health Record Use Variation

ByPhillip D. Jenkins, MD,Gary Grunkemeier, PhD,Elizabeth Weirich, DO,An Dinh, MS,Ruchi Thanawala, MD, MS,Jeffrey A. Gold, MD,Julie Doberne, MD, PhD

January 22nd 2026

A Health Economic Evaluation of Digital Digestive Care Management

ByMartha Shepherd, DO, MPH,Pen-Che Ho, MS,David Hines, BA,Jon Harris-Shapiro, BA,Dena Bravata, MD, MS,Christopher M. Whaley, PhD,K. Davina Frick, PhD,Emmanuel F. Drabo, PhD,Ron Z. Goetzel, PhD

January 21st 2026

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

ByShamsi Atefeh, PhD

January 15th 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

eAppendix

Articles in this issue

Newsletter

Related Content

Ambient AI Tool Adoption in US Hospitals and Associated Factors

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

Specialty and Operator Status Influence Electronic Health Record Use Variation

A Health Economic Evaluation of Digital Digestive Care Management

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Trending on AJMC

Unexplained Pauses Hit Nearly Half of Monthly-Updated CDC Databases, Raising Transparency Concerns

5 Ongoing Phase 3 Trials in Hematologic Malignancies

CRC Becomes Leading Cause of Cancer-Related Death in Younger Adults, Highlighting Prevention Gaps

ACE Inhibitors Linked to Reduced Mortality in Patients with Idiopathic Pulmonary Fibrosis

Clinical Trial Data Signal a New Era for Atopic Dermatitis, Melanoma, and Psoriasis